# Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC)

> **NCT07023432** · PHASE2 · NOT_YET_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 78 (estimated)

## Conditions studied

- Active Surveillance
- Clear Cell Renal Cell Carcinoma

## Interventions

- **DRUG:** Belzutifan
- **OTHER:** Active Surveillance

## Key facts

- **NCT ID:** NCT07023432
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-03
- **Primary completion:** 2028-04-14
- **Final completion:** 2030-04-14
- **Target enrollment:** 78 (ESTIMATED)
- **Last updated:** 2025-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07023432

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07023432, "Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07023432. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*